Advanced Solid Tumors
Conditions
Brief summary
To monitor how often side effects that meet specific criteria (known as Dose Limiting Toxicities, DLTs) happen during the first 21 days from the first dose and how often side effects, serious side effects, DLTs, side effects causing treatment to stop, or deaths happen until 30 days after the last treatment.
Detailed description
To track whether participants’ tumors shrink and how long such responses last, as judged by study doctors, up to 3 years from the first treatment and monitor how BMS-986517 and its main components move through and are processed by the body up to 30 days after the last treatment.
Interventions
DRUGBMS-986517
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To monitor how often side effects that meet specific criteria (known as Dose Limiting Toxicities, DLTs) happen during the first 21 days from the first dose and how often side effects, serious side effects, DLTs, side effects causing treatment to stop, or deaths happen until 30 days after the last treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To track whether participants’ tumors shrink and how long such responses last, as judged by study doctors, up to 3 years from the first treatment and monitor how BMS-986517 and its main components move through and are processed by the body up to 30 days after the last treatment. | — |
Countries
Denmark
Outcome results
None listed